SBI Securities Co. Ltd. Invests $464,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

SBI Securities Co. Ltd. acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 651 shares of the biopharmaceutical company’s stock, valued at approximately $464,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Mizuho Securities USA LLC grew its position in Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 3,231 shares during the last quarter. Golden State Equity Partners grew its position in Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 1,272 shares during the last quarter. Finally, Fagan Associates Inc. grew its position in Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after purchasing an additional 3,832 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $675.49 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a fifty day moving average of $697.13 and a two-hundred day moving average of $859.13. The stock has a market capitalization of $73.85 billion, a PE ratio of 17.65, a P/E/G ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the business posted $11.86 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Ratings Changes

Several analysts have weighed in on REGN shares. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Finally, BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.